CML-BC

AcronymDefinition
CML-BCChronic Myelogenous Leukemia in Blast Crisis
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Oliver Ottman, of the Johann Wolfgang Goethe Universitat in Frankfurt-am-Main, Germany, and his colleagues conducted an open-label, phase II study to evaluate the efficacy of nilotinib in patients with imatinib-resistant or -intolerant CML in blast crisis (CML-BC) or relapsed/refractory Ph+ ALL.
In CML-BC patients, the most frequent grade 3-4 nonhematologic adverse events were pneumonia (11%), pyrexia (6%), diarrhea (4%), and asthenia (4%).
Contributing Writer Investigator Assessment of Best Response to Nilotinib in Patients With CML-BC Myeloid Lymphoid Unknown Type (n = 87) (n = 27) (n = 6) Hematologic response 36% 37% 17% Stable disease 31% 26% 33% Progressive disease 18% 19% 33% Not evaluable 8% 4% 0% Missing 7% 15% 17% Note: Percentages may not add up to 100% because of rounding.